exRNAdisease

Entry Detail

---



General Information

Database ID: exR0275326 RNA Name: hsa-miR-143-3p RNA Type: miRNA Chromosome: chr5 Starnd: + Coordinate: Start Site(bp): 149428978 End Site(bp): 149428998 External Links: hsa-miR-143-3p

Disease Information

Disease Name: Advanced Adenoma Disease Category: Cancers MeSH ID: D000236 Type: Neoplasms/Neoplasms, Glandular and Epithelial Alias: Adenoma//Adenomas//Adenoma, Follicular//Adenomas, Follicular//Follicular Adenoma//Follicular Adenomas//Adenoma, Trabecular//Adenomas, Trabecular//Trabecular Adenoma//Trabecular Adenomas//Adenoma, Monomorphic//Adenomas, Monomorphic//Monomorphic Adenoma//Monomorphic Adenomas//Adenoma, Papillary//Adenomas, Papillary//Papillary Adenoma//Papillary Adenomas//Adenoma, Basal Cell//Adenomas, Basal Cell//Basal Cell Adenoma//Basal Cell Adenomas//Adenoma, Microcystic//Adenomas, Microcystic//Microcystic Adenoma//Microcystic Adenomas

Expression Detail

GEO ID: GSE25609 Description: Plasma microRNA profiling by microarray elucidates several candidate biomarkers for colorectal cancer screening Experimental Design: Cancer vs Control Case Disease Type: Advanced Adenoma Case Disease SubType: NA Case Sample: Advanced Adenoma Post surgery Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ACVR1B chr12 51951699 51997078 + BTF3L4 chr1 52056199 52090716 + BTG2 chr1 203305491 203309602 + CAPZB chr1 19338775 19485539 - CDK6 chr7 92604921 92836594 - CELSR2 chr1 109249539 109275751 + CIT chr12 119685791 119877320 - DEGS1 chr1 224175756 224193441 + DYRK1B chr19 39825350 39834201 - EFNA3 chr1 155078837 155087538 + FOSL2 chr2 28392448 28417317 + IGFBP5 chr2 216672105 216695549 - KRIT1 chr7 92198969 92246166 - MAP3K3 chr17 63622415 63696303 + NES chr1 156668763 156677407 - PACS1 chr11 66070272 66244744 + PATL1 chr11 59636716 59669037 - PNKD chr2 218270392 218346793 + RFWD3 chr16 74621399 74666877 - SLC7A11 chr4 138164097 138242349 - SON chr21 33543038 33577481 + STARD4 chr5 111496033 111512590 - STMN3 chr20 63639705 63657682 - TATDN2 chr3 10248023 10281218 + TFPI chr2 187464230 187565760 - TIGD5 chr8 143597831 143603224 + VPS37C chr11 61130257 61161615 - WSB1 chr17 27294076 27315926 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001247 chr22 46125304 46136418 + hsa_circ_0000711 chr16 68155889 68160513 + hsa_circ_0000431 chr12 102301963 102308010 + hsa_circ_0001168 chr20 47691321 47707559 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC009022.1 chr16 69976297 70065948 - AC091564.7 chr11 6610883 6616594 - AC245884.8 chr19 54438665 54439544 - DHRS4-AS1 chr14 23938219 24052555 - LINC00667 chr18 5237826 5290608 + LZTS1-AS1 chr8 20275773 20290458 + MALAT1 chr11 65497688 65506516 + MCM3AP-AS1 chr21 46229196 46259390 + OIP5-AS1 chr15 41283990 41309737 + Display:

Experiment Detail

GEO ID: GSE25609 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 826 Sample treatment protocol: Briefly, samples were centrifuged at 1,600×g for 10 min at 4 ºC to spin down blood cells, and plasma was transferred into new tubes, followed by further centrifugation at 16,000×g for 10 minutes at 4ºC to completely remove cellular components. RNA Extract protocol: NA RNA library preparation protocol: Biotinylated cDNA were prepared with the Illumina® TotalPrep™ RNA Amplification Kit (Ambion).

Reference

PMID: 23267864 Title: Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study Author: Gir¨¢ldez MD, Lozano JJ, Ram¨ªrez G, Hijona E, Bujanda L, Castells A, Gironella M Journal: Clin Gastroenterol Hepatol. 2013 Jun;11(6):681-8.e3. Description: We investigated whether plasma levels of miRNA can differentiate patients with CRC from healthy individuals. We also investigated whether plasma samples from patients with premalignant neoplastic lesions, such as advanced adenomas (AAs), also had a different expression pattern of miRNAs.